Obesity Medicine

VIDEO Interview: The COVID-19 pandemic has closed what discussion remained about the status of obesity as a disease, according to obesity expert Donna Ryan, MD.

WATCH: The FDA approval of semaglutide 2.4 mg for adults with obesity was "by far the big event in 2021," said Donna Ryan, MD. More from our look back/look ahead interview, here.

Using Mendelian randomization, a new study found in particular that waist-hip ratio may be a more important predictor of hospitalization than BMI.

Take this quick quiz to test your knowledge of recent advances most likely to have an impact on weight management in your practice.

Among patients with obesity, prior weight loss achieved with bariatric surgery was associated with a 60% lower risk of severe COVID-19, suggests new research.

Increases in obesity parameters significantly increased risk of incident heart failure in persons with diabetes, but not without diabetes, in a large community-based cohort study.

The Guideline Toplines slide-show feature offers busy primary care physicians at-a-glance summaries of new and updated clinical guidelines across therapeutic areas.

Find out how effective each of 8 ACC/AHA-recommended non-drug interventions is at reducing BP (in mm Hg) in adults with hypertension and normal BP.

Obesity and its causes are the focus of extensive research evaluating new therapeutic targets. Get an at-a-glance update on progress and FDA approvals during 2021

In patients with biopsy-proven NASH, the SPLENDOR study is the first to report a medical modality associated with decreased risk of major adverse events.

Weight bias themes in primary care are the subject of contemporary research. Which options you choose to these 8 questions may offer insight into your own unconscious prejudices.

In our latest podcast episode, an obesity expert talks weight bias in health care, its widespread impact, and the advocacy work that is being done to change the narrative.

Weight bias or stigma in healthcare settings, whether explicit or implicit, may keep patients from getting care. Find a review of the recent literature in this slide show.

Semaglutide 2.4 mg led to clinically significant weight loss and improvements in cardiometabolic risk factors in adults with moderate or severe obesity, suggests new research from ObesityWeek 2021.

The evidence that obesity is pathophysiologic dysfunction in the human body places it squarely in the realm of chronic disease, according to obesity specialist Kaplan. Let’s treat it accordingly.

Primary care leadership is essential to the future of obesity medicine, says Kaplan, but treatment needs to be within the normal scope of primary care practice. Hear him explain.

Recognizing obesity as chronic pathophysiologic dysfunction and explaining that to a patient will make them remarkably more receptive to all other discussions about treatment, says obesity specialist Kaplan.

ObesityWeek 2021. Weight loss with semaglutide was more than 2 times greater than with liraglutide in the 68-week placebo-controlled trial of the 2 GLP-1 RAs.

ObesityWeek 2021: Regular engagement in online behavioral obesity treatment program within primary care network produced clinically significant weight loss in new study.

A clinical psychologist from the Mayo Clinic Bariatric Center in Jacksonville, FL, explains and corrects key misperceptions that inhibit open discussion of the therapy.

ObesityWeek 2021: New study highlights protective effects of medical weight management during COVID-19 pandemic.

ObesityWeek 2021. Liraglutide helped patients who regained weight after successful gastric bypass surgery re-achieve their lowest weight with an acceptable safety profile.

ObesityWeek 2021: Weight loss support delivered via pandemic-driven telehealth resulted in clinically significant weight loss, report 2 different research teams.

When addressing mental health with patients with obesity, a thoughtful approach that balances psychological health and weight loss is critical, explains Dr Ethan Lazarus.

EASD 2021: Patients with metabolically healthy obesity are nearly 33% more likely to develop heart failure and atrial fibrillation than healthy persons of normal weight, suggests new analysis.